Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer
Shreya Gupta, James D. McDonald, Reed I. Ayabe, Tahsin M. Khan, Lauren A. Gamble, Surajit Sinha, Cathleen Hannah, Andrew M. Blakely, Jeremy L. Davis, Jonathan M. Hernandez
Abstract
positive human tumor lines and has been shown to be potent in complement-dependent cytotoxicity assays and antibody-dependent cell mediated cytotoxicity assays. In patients with metastatic CA 19-9 producing pancreatic adenocarcinoma, MVT-5873 treatment has been shown to decrease serum CA 19-9 levels and prevent tumor progression. The use of perioperative MVT-5873 has the potential to reduce recurrence rates and prolong survival after resection. This trial may open the door for investigation of additional and/or synergistic agents in the immediate peri-operative period and usher in a new paradigm in the management of surgically treated cancers. TRIAL REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT03801915?term=MVT&rank=3.